The Department of Veterans Affairs does not cover stem cell therapy for joint damage, arthritis, spinal discs, or anti-aging purposes. At Medical Frontier, we set out what payers’ written policies say before you pay for an unproven treatment. Federal regulations strictly exclude biological therapies that lack product approval from the Food and Drug Administration, meaning outpatient regenerative procedures require complete self-pay funding.
Does the VA Cover Stem Cell Therapy?
The Department of Veterans Affairs (VA) does not cover stem cell therapy for joint pain, degenerative disc disease, soft tissue injuries, or systemic wellness. Under federal regulation 38 CFR 17.38, VA health care excludes drugs, biologicals, and medical devices that lack approval from the Food and Drug Administration (FDA). Outpatient pain and orthopedic injections fall squarely under this exclusion. Military service members and dependents covered through TRICARE face a similar rule: TRICARE excludes any medical procedure whose safety and efficacy are not established.
Both systems maintain clear exceptions for hospital-based stem cell transplants. The VA and TRICARE provide coverage for bone marrow and hematopoietic cell transplants to treat aggressive blood cancers, including leukemia, lymphoma, and multiple myeloma. If a patient seeks treatment outside an oncology transplant unit, coverage disappears. Many private health plans apply similar exclusions, as detailed in our guide to commercial insurance coverage.
Neither the VA nor TRICARE reimburses commercial regenerative centers for cellular therapy. Any veteran who pursues an outpatient injection at a private facility must fund the full procedure without government reimbursement.
What VA’s Benefits Rule Says
Federal regulation governs every service the VA provides. Under 38 CFR 17.38(b), the Veterans Health Administration provides care only if it is needed to promote, preserve, or restore health in accord with generally accepted standards of medical practice. Unproven cellular injections do not meet that clinical threshold.
The direct legal bar sits in 38 CFR 17.38(c)(3), which explicitly excludes from the VA medical benefits package:
“Drugs, biologicals, and medical devices not approved by the Food and Drug Administration unless the treating medical facility is conducting formal clinical trials under an Investigational Device Exemption (IDE) or an Investigational New Drug (IND) application, or the drugs, biologicals, or medical devices are prescribed under a compassionate use exemption.”
This regulation defines strict boundaries for unapproved therapies:
- Formal clinical trials: The facility must administer the biologic under an FDA-sanctioned protocol using an Investigational New Drug (IND) application or Investigational Device Exemption (IDE).
- Compassionate use exemption: A doctor gets FDA permission to give one patient an unapproved product outside a trial.
Outpatient orthopedic injections do not qualify under either exception. When an independent pain office offers stem cell injections for knee osteoarthritis, it is selling an unapproved biologic outside an authorized research structure. The VA cannot pay for the injection under federal law. To understand federal regulatory boundaries, review our analysis of FDA status for regenerative medicine.
VA Community Care and Outside Clinics
The VA community care program does not fund private stem cell injections. Veterans frequently ask whether community care can pay an outside orthopedic practice when a local VA medical center does not offer regenerative medicine. The rules governing the VA community care program prevent this workaround.
To obtain community care, you must receive prior approval from the VA. The VA issues authorizations exclusively for treatments that fit within the standard medical benefits package defined by federal law. If a service is excluded under 38 CFR 17.38, a VA care coordinator cannot approve an outside referral for it.
A clinic that promises VA or TRICARE will pay for a joint or anti-aging stem cell injection is showing a red flag, since community care needs VA’s approval before care starts and the unapproved-biologic exclusion still applies.
What VA Does Cover: Transplants
The VA covers stem cell therapy when provided as an inpatient cellular transplant for serious blood disorders and cancers. As documented by the Veterans Health Administration transplant program, the VHA has offered solid organ transplant services since 1962 and bone marrow transplant services since 1982. These procedures use blood-forming stem cells to rebuild bone marrow destroyed by high-dose chemotherapy.
The VA’s official transplant locations list stem cell transplants at medical centers in Seattle, Washington, and Nashville, Tennessee, with the Nashville facility also offering chimeric antigen receptor T-cell (CAR-T) therapy. On October 1, 2024, the VA Tennessee Valley Healthcare System opened a dedicated stem cell processing lab. The VA describes TVHS as the only VA in the country with a fully intact stem cell transplant program, supporting the treatment of aggressive blood cancers and autoimmune disease.
These specialized programs treat complex, life-threatening diagnoses:
- Acute and chronic leukemias
- Hodgkin and non-Hodgkin lymphomas
- Multiple myeloma
- Severe hematologic and immune conditions
The clinical setting of a bone marrow transplant shares no common ground with an outpatient pain facility. A private facility offering injections for knees, hips, or spinal discs is administering unapproved products that fall completely outside the VA transplant system. Our guide on stem cell therapy versus transplants explains the scientific differences between these interventions.
TRICARE and Stem Cell Therapy
TRICARE excludes stem cell therapy for orthopedic wear and back pain under its unproven-care rule. Under TRICARE Policy Manual Chapter 1, Section 2.1, any drug, device, medical treatment, or procedure whose safety and efficacy has not been established is unproven and is excluded from coverage. This exclusion explicitly applies to any drug or device that cannot be lawfully marketed without FDA approval that has not been given, extending to all services directly related to the unproven procedure.
TRICARE covers stem cell transplants for cancers and blood diseases. Under TRICARE Policy Manual Chapter 4, Section 23.1, coverage is authorized for autologous and allogeneic bone marrow and peripheral stem cell transplants, as well as allogeneic umbilical cord blood transplants, for oncologic, hematologic, or lymphoproliferative disease with curative potential. Covered conditions include non-Hodgkin lymphoma, Hodgkin disease, neuroblastoma, acute leukemias, and multiple myeloma. TRICARE Prime beneficiaries require a Primary Care Manager referral and contractor authorization before proceeding.
The same policy section explicitly excludes experimental cellular uses:
- Autologous umbilical cord blood transplant: Excluded as unproven.
- Transplants for multiple sclerosis: Peripheral stem cell and bone marrow transplants for multiple sclerosis are classified as unproven.
- Transplants for arthritis: Immunoablative therapy with transplant for rheumatoid arthritis and juvenile idiopathic arthritis is unproven and not covered.
- Research services: Any services that are part of a grant or research program are excluded.
If an injection is sought for knee osteoarthritis or degenerative back pain, TRICARE’s unproven-care exclusion (Chapter 1, Section 2.1) applies.
TRICARE and PRP
TRICARE does not cover platelet-rich plasma (PRP) injections for any medical condition. Patients looking for alternatives to stem cell therapy frequently ask about PRP as a lower-cost biological option.
Under TRICARE Policy Manual Chapter 4, Section 6.1, the policy states that platelet-rich plasma is unproven for all indications. This policy took effect October 1, 2024, for the exclusion of PRP for all indications.
TRICARE maintains an emerging technology review pathway through the TRICARE Provisional Coverage Program. This program currently lists specific emerging technologies, including monoclonal antibodies for Alzheimer’s disease and leadless cardiac pacemakers. Platelet-rich plasma is not listed on the provisional coverage schedule. TRICARE beneficiaries receiving PRP for tendinitis, joint arthritis, or spine pain must pay out of pocket. To review national commercial coverage standards for this procedure, consult our guide on insurance coverage for PRP.
VA and TRICARE at a Glance
Coverage rules across both military healthcare systems align around FDA approval and proven clinical standards.
| Treatment Type | VA Health Care Status | TRICARE Coverage Status | Financial Responsibility |
|---|---|---|---|
| Orthopedic stem cell injection (knee, hip, shoulder) | Excluded under 38 CFR 17.38(c)(3) | Excluded as unproven (Chapter 1, Sec 2.1) | 100 percent self-pay |
| Intravenous wellness or anti-aging infusion | Excluded under 38 CFR 17.38(c)(3) | Excluded as unproven (Chapter 1, Sec 2.1) | 100 percent self-pay |
| Platelet-rich plasma (PRP) for joints | No VA PRP policy found | Excluded for all indications (Oct 1, 2024) | 100 percent self-pay |
| Stem cell transplant for acute leukemia | Covered at designated transplant centers | Covered with prior authorization | Standard cost-sharing |
| Stem cell transplant for multiple sclerosis | No VA policy found | Excluded as unproven (Chapter 4, Sec 23.1) | Not covered |
| Qualifying cancer clinical-trial care | Allowed in formal IND/IDE trials (38 CFR 17.38(c)(3)) | Routine care covered (Chapter 7, Sec 24.3) | Sponsor covers biologic |
The Free Route: Clinical Trials
Veterans seeking legitimate, no-cost access to investigational cellular treatments can find it through formal clinical trials. As outlined in VA research programs, investigators study regenerative medicine to learn how to restore tissue and organ function, including spinal cord function, lost to aging, injury, or disease. The VA actively points veterans toward joining a VA-sponsored clinical trial.
Federal healthcare policies accommodate legitimate research participation:
- VA regulations: Under 38 CFR 17.38(c)(3), an investigational biologic is permitted when the medical facility conducts formal clinical trials under an FDA Investigational New Drug (IND) or Investigational Device Exemption (IDE) application.
- TRICARE regulations: Under TRICARE Policy Manual Chapter 7, Section 24.3, TRICARE covers standard medical services associated with National Cancer Institute (NCI) sponsored or approved Phase I through Phase IV cancer clinical trials for selected eligible patients with preauthorization. The study sponsor funds the investigational agents.
In an authorized trial, the research sponsor typically provides the experimental treatment without charging the participant. A commercial clinic that asks a veteran to pay to join a “patient registry” or “clinical study” is selling an unapproved cash treatment. Every legitimate trial is cataloged on ClinicalTrials.gov. We break down these differences in our guide on clinical trials versus cash clinics.
What You Pay Without Coverage
Because federal programs deny payment for outpatient cellular treatments, patients who proceed with private care must cover all clinic fees directly. Medical Frontier’s published US self-pay ranges are:
- Single joint injection: A regenerative injection in one knee, shoulder, or hip ranges from $3,000 to $8,000. You can review specific joint data in our knee stem cell cost guide.
- Spine or bilateral joints: Injections into multiple joints or spinal discs range from $6,000 to $15,000.
- Intravenous systemic infusions: Systemic cellular treatments range from $15,000 to more than $30,000.
- Platelet-rich plasma: Standard PRP injections cost $400 to $2,000 per session, with a multi-injection series totaling $1,500 to $6,000, as outlined in our PRP injection cost breakdown.
A clinic that promises it can bill the VA or TRICARE through creative coding presents a major financial risk. Knowing how to vet a clinic helps you spot this tactic before signing financial paperwork.
Closing Guidance on Military and Veteran Coverage
Neither the VA nor TRICARE covers stem cell injections or PRP for joint conditions, back pain, or wellness applications. Both cover hospital stem cell transplants treating aggressive blood cancers and hematologic disorders.
If you choose to explore regenerative therapy, expect to pay the entire clinic charge with personal funds. Compare standard market pricing using our interactive cost estimator, and review our comprehensive stem cell cost guide to evaluate out-of-pocket expenses. If you are comparing your military benefits against Medicare, consult our guide on Medicare stem cell coverage to review federal guidelines across systems.
Frequently asked questions
Does the VA cover stem cell therapy?
The VA covers stem cell therapy only as an established hospital transplant for specific blood cancers and hematologic disorders. Under federal regulations at 38 CFR 17.38, the VA excludes unapproved biologics, meaning outpatient stem cell injections for knees, shoulders, or back pain are not covered.
Where can veterans get free stem cell therapy?
Veterans can receive no-cost investigational cellular therapies by enrolling in an approved clinical trial. In legitimate studies registered on ClinicalTrials.gov, the trial sponsor provides the investigational product without charging the patient thousands of dollars.
Does VA community care cover stem cell injections?
No, VA community care does not pay for private stem cell injections. Community care requires advance authorization from the VA, and outside providers remain strictly bound by the same federal benefit exclusions against unapproved biological products.
Does TRICARE cover stem cell therapy?
TRICARE covers stem cell transplants for proven indications such as leukemias, lymphomas, and multiple myeloma, but excludes stem cell therapy for joint pain, multiple sclerosis, and arthritis. Under TRICARE policy, any treatment lacking established safety and efficacy is classified as unproven.
Is PRP injection covered by TRICARE?
No, platelet-rich plasma injections are not covered by TRICARE. Effective October 1, 2024, the TRICARE Policy Manual classifies platelet-rich plasma as unproven for all indications, leaving patients entirely responsible for the cost of joint or tendon procedures.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.